In 2020, Moderna had a gain of more than 430% thanks to its vaccine. This year so far, the price increased by almost 300%. Are Wall Street analysts right to expect a share price that’s about $100 lower?
Moderna is one of the few healthcare companies that created a coronavirus vaccine. Following its approval, its stock price increased by 700%, reaching $436.39. May this be the right time to short Moderna stock or is there still room to grow?
If you want to find out if Moderna is a buy right now and where you can open a long or short position, check out the following sections.
How & Where to Buy Moderna Stock Online
If you think Moderna’s share price will increase or decrease, you can speculate on it by opening a long or short position. You need to register with an online broker that provides access to coronavirus stocks, such as these ones:
eToro is one of the world's leading multi-asset trading platforms offering some of the lowest commission and fee rates in the industry. It's social copy trading features make it a great choice for those getting started.
Financial company driven by technology and offering all-in-one self-directed investment platform that provides excellent user experience.
What Is Moderna?
Moderna made the headlines as it developed one of the main coronavirus vaccines. The company specialises in vaccine technology using messenger RNA and currently has only one commercial product, although it has 24 more vaccine candidates for several viruses, including HIV and influenza.
Should I Buy Moderna Today?
For some, Moderna has already proved itself – we mostly had a steady stream of good news. Undoubtedly, setbacks are expected when dealing with drugs and vaccines, but the company managed to handle most of them. This year, for instance, the company submitted a set of positive results to the FDA regarding teen trials and booster trials.
Analysts expected Moderna to decrease this year – perhaps considering that investors bought shares on the vaccine development rumours and will sell them on the news. However, there may be more catalysts for share price increases. For instance, FDA may grant the approval to use the vaccine in teens.
There’s also more to this biotech stock than the coronavirus vaccine. The next product may be a vaccine for cytomegalovirus (CMV), a virus that doesn’t have a vaccine right now and is dangerous for people with weak immune systems and pregnant women. Any success related to one of its 24 products in the pipeline right now may keep Moderna in a bullish run.
Moderna Price Prediction 2021
Analysts are quite bearish on Moderna’s estimated share price in the next 12 months. There is a low estimate of $85 and a high estimate of only 7.2% higher than today’s share price. This may be a great opportunity to open a long or short position, depending on whether you think Moderna has what it takes to remain ahead of the competition.